Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal …
L Chinezu, A Vasiljevic, E Jouanneau, P François… - Human pathology, 2014 - Elsevier
Medical treatment of endocrine pituitary tumors with somatostatin analogs depends on tumor
type and somatostatin receptor (SSTR) expression. Immunohistochemical detection of these …
type and somatostatin receptor (SSTR) expression. Immunohistochemical detection of these …
Role of somatostatin receptors in normal and tumoral pituitary corticotropic cells
LJ Hofland, SWJ Lamberts, RA Feelders - Neuroendocrinology, 2010 - karger.com
Normal and tumoral pituitary corticotropic cells express sst 2 and sst 5, of which sst 5 is the
predominantly expressed receptor subtype. Somatostatin (SS) inhibits pituitary …
predominantly expressed receptor subtype. Somatostatin (SS) inhibits pituitary …
[PDF][PDF] The di Bella method (DBM)
G Di Bella - Neuro Endocrinol Lett, 2010 - metododibella.org
AIMS: the aim of the Di Bella Method (DBM) is to try to overcome the high toxicity level and
the limited efficacy of the current medical treatments for cancer. METHOD: using Melatonin …
the limited efficacy of the current medical treatments for cancer. METHOD: using Melatonin …
[HTML][HTML] Pituitary Adenoma: SSTR2 rs2236750, SSTR5 rs34037914, and AIP rs267606574 Genetic Variants, Serum Levels, and Ki-67 Labeling Index Associations
G Gedvilaite-Vaicechauskiene, L Kriauciuniene… - Medicina, 2024 - mdpi.com
Background and Objectives: This study explores the complex pathogenesis of pituitary
adenomas (PAs), prevalent intracranial tumors in the pituitary gland. Despite their generally …
adenomas (PAs), prevalent intracranial tumors in the pituitary gland. Despite their generally …
[HTML][HTML] Cushing's Disease Manifestation in USP8-Mutated Corticotropinoma May Be Mediated by Interactions Between WNT Signaling and SST Trafficking
E Nerubenko, P Ryazanov, N Kuritsyna… - International …, 2024 - pmc.ncbi.nlm.nih.gov
In the current work, we aimed to evaluate the association of clinical data of Cushing's
disease (CD) patients with USP8 mutation status and to study USP8-related molecular …
disease (CD) patients with USP8 mutation status and to study USP8-related molecular …
[HTML][HTML] Clinical importance of somatostatin receptor 2 (SSTR2) and somatostatin receptor 5 (SSTR5) expression in thyrotropin-producing pituitary adenoma (TSHoma …
B Yu, Z Zhang, H Song, Y Chi, C Shi… - Medical Science Monitor …, 2017 - ncbi.nlm.nih.gov
Background Thyrotropin-secreting pituitary adenomas (TSHomas) are a rare cause of
hyperthyroidism. Somatostatin analogs have proved to be effective for inhibiting pituitary …
hyperthyroidism. Somatostatin analogs have proved to be effective for inhibiting pituitary …
Somatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism and PKD1 mutation
LV Syro, JL Sundsbak, BW Scheithauer, RA Toledo… - Pituitary, 2012 - Springer
A 39-year-old woman with autosomal dominant polycystic kidney disease (ADPKD)
presented with acromegaly and a pituitary macroadenoma. There was a family history of this …
presented with acromegaly and a pituitary macroadenoma. There was a family history of this …
[PDF][PDF] Immunohistochemical expression of somatostatin receptor subtypes 2 and 5 in thyrotropin-secreting pituitary adenomas: a consecutive case series of pituitary …
HJ Fang, YF Li, Y Fu, LY Zhong, YZ Zhang - Int J Clin Exp Pathol, 2017 - e-century.us
Thyrotropin-secreting pituitary adenomas (TSHomas) are a rare cause of hyperthyroidism.
Somatostatin analogue has proved to be effective for inhibiting pituitary hormones secretion …
Somatostatin analogue has proved to be effective for inhibiting pituitary hormones secretion …
[PDF][PDF] A RETROSPECTIVE OBSERVATIONAL STUDY ON CASES OF SARCOMA TREATED WITH THE DI BELLA METHOD: RATIONALE AND EFFECTIVENESS
G Di Bella, V Borghetto, I Moscato, E Costanzo - 2022 - wjpr.s3.ap-south-1.amazonaws.com
Despite all the new developments in cancer therapy, the life expectancy of patients with
sarcoma remains short. Since it was established as a cancer therapy, the Di Bella Method …
sarcoma remains short. Since it was established as a cancer therapy, the Di Bella Method …
[PDF][PDF] A retrospective observational study on cases of anaplastic brain tumors treated with the Di Bella Method: A rationale and effectiveness
G Di Bella, V Borghetto… - Neuroendocrinology …, 2021 - dibellainsieme.org
Despite all the new developments in cancer therapy, the life expectancy of patients with
malignant anaplastic brain tumors and glioblastoma multiform (GBM) remains short. Since …
malignant anaplastic brain tumors and glioblastoma multiform (GBM) remains short. Since …